Medisca is a pharmaceutical compounding company that provides equipment, devices, education services, and ingredients to pharmacists. The company has locations in North America, Australia, and Europe.
In the case of the new facility, Medisca is set to expand its North American operations with the addition of a repackaging and distribution center in Plattsburgh, New York.
The company’s building is set to cover 60,000-square-feet, on 10 acres of land, and will be constructed through an undisclosed ‘significant’ investment.
Through the new space, Medisca will be able to consolidate five different sites into one location, which the company stated will improve operational flow and employee well-being.
Once opened, the site is expected to employ 100 people and is set to be operational in July 2023. The actual completion of the facility is projected for April 2023.
Antonio Dos Santos, Medisca founder and president, stated, “By consolidating our existing space into one single site, we will more than double our capacity to serve our customers. The new facility will offer best-in-class automated workflows and layouts for maximum efficiency and employee wellness, which is at the core of our corporate values.”
Working alongside Medisca will be TDC, a private not-for-profit organization that develops industrial parks with a mission to retain and expand local industry.
TDC is governed by a board of directors composed of business and community leaders from the Clinton County area. The non-profit leases and maintains industrial properties in Plattsburgh, but also states that it helps businesses with resources, suppliers, staff, and financial incentives.
Medisca’s new facility will be based out of TDC’s Banker Road Industrial Park. According to TDC, the building will be comprised of two suites, both with 30,000-square-feet of space. In addition, the facility will also have 1,000-square-feet of office and support space.
The announcement of the new facility arrives a few months after the company was engaged in another investment, by acquiring all IP assets of Maxima Pharmaceuticals. The latter company is based in Edmonton, Canada, where it provides wholesale services for pharmaceutical, orphan drugs, and medical devices.
The purchase of the assets includes Diffusimax and Diffiusimax10 liposomal bases (pluronic lecithin organogel or PLO gel), products that are used in the preparation of compounded topical formulations.
According to Medisca, the two products are the “go-to” topical vehicles for many providers across Canada.